Evidence map›Paper›PMID 40903229›Full record

ArticleInternal medicine (Tokyo, Japan)2026

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Shinsuke Uchikawa, Tomokazu Kawaoka, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Serami Murakami, Ryoichi Miura, Yusuke Johira, Hikaru Nakahara, Yasutoshi Fujii and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Shinsuke UchikawaDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Tomokazu KawaokaDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Aiko TanakaDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Kou HashimotoDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Tomoaki EmoriDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Serami MurakamiDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Ryoichi MiuraDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Yusuke JohiraDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Hikaru NakaharaDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Yasutoshi FujiiDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Hatsue FujinoDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Atsushi OnoDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Eisuke MurakamiDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Daiki MikiDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
C Nelson HayesDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.
Kazuki OhyaDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan.
Nami MoriDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan.
Shintaro TakakiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan.
Yoshio KatamuraDepartment of Gastroenterology, Onomichi General Hospital, Hiroshima Kosei Federation of Agricultural Cooperatives, Japan.
Masataka TsugeLiver Center, Hiroshima University Hospital, Japan.
Shiro OkaDepartment of Gastroenterology, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study aimed to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atez+Bev) as a 2nd line therapy after the administration of durvalumab plus tremelimumab (Dur+Tre) in patients with hepatocellular carcinoma. We focused on the treatment outcomes and adverse event profiles specific to this sequential regimen. Methods A retrospective analysis was conducted on 16 patients who received 2nd line Atez+Bev after Dur+Tre therapy between April 2023 and August 2024 in our hospital and associated institutions. The objective response rate (ORR), disease control rate (DCR), treatment duration, and adverse events were assessed. Results The ORR and DCR for 2nd line Atez+Bev were 25.0% and 75.0%, respectively, thus suggesting favorable disease control. Even among patients who were non-responsive to Dur+Tre, two achieved a tumor response and eight achieved disease control. Regarding safety, pruritus was a common adverse event for both regimens. Colitis and diarrhea were more frequent in the Dur+Tre group, whereas proteinuria, hyperammonemia, and bleeding were more common in the Atez+Bev group. Conclusion This study suggests that Atez+Bev remains a viable option for patients unresponsive to Dur+Tre. Prior Dur+Tre therapy may enhance the immune response within the tumor microenvironment, thereby augmenting the efficacy of Atez+Bev. However, it is important to pay attention to the differences in adverse effect profiles between the two regimens.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabdurvalumabtremelimumabatezolizumab plus bevacizumabdurvalumab plus tremelimumabhepatocellular carcinomasequential therapy

Identifiers

PMID40903229
PMCPMC13175667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.